Comparative analysis of minimal residual disease detection using four-color flow cytometry, consensus IgH-PCR, and quantitative IgH PCR in CLL after allogeneic and autologous stem cell transplantation

被引:63
作者
Böttcher, S
Ritgen, M
Pott, C
Brüggemann, M
Raff, T
Stilgenbauer, S
Döhner, H
Dreger, P
Kneba, M
机构
[1] Univ Kiel, Dept Med 2, D-24116 Kiel, Germany
[2] Univ Ulm, Dept Internal Med 3, D-89069 Ulm, Germany
[3] Allgemein Krankenhaus St Georg, Dept Hematol, Hamburg, Germany
关键词
CLL; stem cell transplantation; minimal residual disease; flow cytometry; real-time PCR;
D O I
10.1038/sj.leu.2403478
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The clinically most suitable method for minimal residual disease (MRD) detection in chronic lymphocytic leukemia is still controversial. We prospectively compared MRD assessment in 158 blood samples of 74 patients with CLL after stem cell transplantation (SCT) using four-color flow cytometry ( MRD flow) in parallel with consensus IgH-PCR and ASO IgH real-time PCR ( ASO IgH RQ-PCR). In 25 out of 106 samples (23.6%) with a polyclonal consensus IgH-PCR pattern, MRD flow still detected CLL cells, proving higher sensitivity of flow cytometry over PCR-genescanning with consensus IgH-primers. Of 92 samples, 14 (15.2%) analyzed in parallel by MRD flow and by ASO IgH RQ-PCR were negative by our flow cytometric assay but positive by PCR, thus demonstrating superior sensitivity of RQ-PCR with ASO primers. Quantitative MRD levels measured by both methods correlated well ( r = 0.93). MRD detection by flow and ASO IgH RQ-PCR were equally suitable to monitor MRD kinetics after allogeneic SCT, but the PCR method detected impending relapses after autologous SCT earlier. An analysis of factors that influence sensitivity and specificity of flow cytometry for MRD detection allowed to devise further improvements of this technique.
引用
收藏
页码:1637 / 1645
页数:9
相关论文
共 52 条
[1]  
AUBIN J, 1995, LEUKEMIA, V9, P471
[2]   Lymphoid reconstitution after autologous PBSC transplantation with FACS-sorted CD34+ hematopoietic progenitors [J].
Bomberger, C ;
Singh-Jairam, M ;
Rodey, G ;
Guerriero, A ;
Yeager, AM ;
Fleming, WH ;
Holland, HK ;
Waller, EK .
BLOOD, 1998, 91 (07) :2588-2600
[3]   Minimal residual disease detection in childhood precursor-B-cell acute lymphoblastic leukemia: relation to other risk factors. A Children's Oncology Group study [J].
Borowitz, MJ ;
Pullen, DJ ;
Shuster, JJ ;
Viswanatha, D ;
Montgomery, K ;
Willman, CL ;
Camitta, B .
LEUKEMIA, 2003, 17 (08) :1566-1572
[4]   Improved assessment of minimal residual disease in B cell malignancies using fluorogenic consensus probes for real-time quantitative PCR [J].
Brüggemann, M ;
Droese, J ;
Bolz, I ;
Lüth, P ;
Pott, C ;
von Neuhoff, N ;
Scheuering, U ;
Kneba, M .
LEUKEMIA, 2000, 14 (08) :1419-1425
[5]   Analysis of residual disease in chronic lymphocytic leukemia by flow cytometry [J].
Cabezudo, E ;
Matutes, E ;
Ramrattan, M ;
Morilla, R ;
Catovsky, D .
LEUKEMIA, 1997, 11 (11) :1909-1914
[6]  
Campana D, 1999, CYTOMETRY, V38, P139, DOI 10.1002/(SICI)1097-0320(19990815)38:4<139::AID-CYTO1>3.0.CO
[7]  
2-H
[8]   FLOW CYTOMETRIC ANALYSIS OF WHOLE-BLOOD LYSIS, 3 ANTICOAGULANTS, AND 5 CELL PREPARATIONS [J].
CARTER, PH ;
RESTORUIZ, S ;
WASHINGTON, GC ;
ETHRIDGE, S ;
PALINI, A ;
VOGT, R ;
WAXDAL, M ;
FLEISHER, T ;
NOGUCHI, PD ;
MARTI, GE .
CYTOMETRY, 1992, 13 (01) :68-74
[9]   Ig V gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukemia [J].
Damle, RN ;
Wasil, T ;
Fais, F ;
Ghiotto, F ;
Valetto, A ;
Allen, SL ;
Buchbinder, A ;
Budman, D ;
Dittmar, K ;
Kolitz, J ;
Lichtman, SM ;
Schulman, P ;
Vinciguerra, VP ;
Rai, KR ;
Ferrarini, M ;
Chiorazzi, N .
BLOOD, 1999, 94 (06) :1840-1847
[10]   Atypical lymphocytic leukemia and mantle cell lymphoma immunologically very close:: flow cytometric distinction by the use of CD20 and CD54 expression [J].
Deneys, V ;
Michaux, L ;
Leveugle, P ;
Mazzon, AM ;
Gillis, E ;
Ferrant, A ;
Scheiff, JM ;
De Bruyère, M .
LEUKEMIA, 2001, 15 (09) :1458-1465